P-095 Experience with Ustekinumab in Mexican Patients with Moderate-Severe Anti-TNF Resistant Crohnʼs Disease
نویسندگان
چکیده
منابع مشابه
Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease
The advent of anti-tumor necrosis factor (TNF)-α therapy has been a major advance in the medical management of Crohn's disease (CD). However, a significant proportion of patients with CD do not respond adequately to treatment with these agents. Primary and secondary nonresponse to anti-TNFα therapy represents a common clinical challenge, and highlights the need for the development of additional...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
OBJECTIVES Anti-TNF therapy has improved outcomes for patients with highly active RA. Less is known about its effectiveness in patients with lower disease activity. The aim of this analysis is to compare the response to anti-TNF therapy between RA patients with high (DAS28 > 5.1) and moderate (DAS28 > 3.2-5.1) disease activity. METHODS A total of 4687 anti-TNF and 344 DMARD patients with high...
متن کاملA randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
BACKGROUND & AIMS Interleukin-12 and interleukin-23 are inflammatory cytokines implicated in Crohn's disease pathophysiology. Ustekinumab is a monoclonal antibody against the p40 subunit of interleukin-12/23. METHODS We performed a double-blind, cross-over trial of the clinical effects of ustekinumab in 104 patients with moderate-to-severe Crohn's disease (population 1). Patients were given s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Inflammatory Bowel Diseases
سال: 2016
ISSN: 1078-0998
DOI: 10.1097/01.mib.0000480200.55880.3f